| |
T002: Independent Advisory Boards |
|
|
| International Advisory Board |
|
| An International Advisory Board ("IAB") - composed of 7 international experts in the immunological, virological or vaccine field. The IAB will provide independent advice to the Sponsor in taking decisions, alternative strategies and solutions in any critical situations that may ensue from the study. |
| Jay A. Levy, MD |
| Professor in Residence, Department of Medicine, Division Hematology. Director of the Laboratory for Tumor and AIDS Virus Research, University of California, School of Medicine San Francisco. |
| Gian Vincenzo Zuccotti, MD |
| Associate Professor, "Università degli Studi di Milano", Children's Hospital Director "AO Luigi Sacco", Milan, Italy. |
| Lorenzo Moretta, MD |
| Scientific Director, Children's Hospital "G. Gaslini", Genova. Professor in Residence, Department of General Pathology and Physiopathology of the "Università di Genova", Genova, Italy. |
| Saladin Osmanov, Dr |
| World Health Organization (WHO) and UNAIDS Coordinator, Geneva. WHO Coordinator for the HIV Vaccine Initiative, Geneva, Switzerland. |
| Jan Holmgren, Ph.D. |
| Professor of Medical Microbiology and Immunology at Goteborg University; Director of the Goteborg University Vaccine Research Institute (GUVAX), Sweden. Specialist for mucosal vaccine against cholera. |
| Carlos Alberto Guzman, Ph.D. |
| Scientific Director, Department of Vaccinology, Helmholtzt Centre for Infection Research, Braunschweig, Germany. Professor of Medical Microbiology, MHH Hannover Medical School, Hannover, Germany. Vaccine, immunomodulator, delivery system for DNA vaccines and gene therapy expert. |
| Frank Goebel, M.D. |
| Professor in Residence, Department of Infectious Diseases and Tropical Medicine, University of Munich, Germany. |
|
| Data Safety Monitoring Board |
|
| A Data Safety Monitoring Board ("DSMB") - formed by international experts of well-documented experience in the field of HIV/AIDS. The DSMB will monitor the safety of the vaccine by periodically evaluating all data during the trial. |
| Dr. Patrizia Popoli |
| Research Director, Department of Drug Research and Evaluation; Pharmacovigilance and Neuropharmacology Expert, Istituto Superiore di Sanità, Rome, Italy. |
| Dr. Francesca Menniti Ippolito |
| Researcher, National Centre for epidemiology, surveillance and health; Epidemiologist and Biostatistician for Clinical Epidemiology, Infectious Diseases and Pharmacoepidemiology, Istituto Superiore di Sanità, Rome, Italy. |
| Dr. Andrea Gori |
| Director, Division of Infectious Diseases, "Vecchio Ospedale San Gerardo", Monza, Italy. Expert in Hiv, Infectious and Tropical Diseases. |
| Prof. Veronica Miller |
| Professor, George Washinghton University, USA; Director of the "Forum for collaborative HIV Research"; Co- Founder and coordinator of the EuroGuidelines for the standardization between countries for public health management. Advisor for several companies and institutional committees, such as "FDA Antiviral Advisory Committee". |
| Dr. Josè Maria Mirò |
| Reasearcher, Infectious Disease Service of the University of Barcelona, Sunyer Hospital Clinic - Institut d'Investigacions Biomediques August (IDIBAPS), Barcelona, Spain. |
|
| Community Advisory Board |
|
| A Community Advisory Board ("CAB") - constituted by exponents of non governmental organisations (NGOs) active in the field of AIDS. The CAB will assist the Sponsor in supporting the interests and well being of the patients. |
| R. Biondi |
| NADIR Onlus - HIV Treatment Group. |
| V. Cantarella |
| GITA - Gruppo Italiano Terapie Anti-HIV. |
| M. Formisano |
| NPS - Network Persone Sieropositive. |
| A. Poto |
| ARCIGAY |
